全文获取类型
收费全文 | 288910篇 |
免费 | 45924篇 |
国内免费 | 12387篇 |
专业分类
耳鼻咽喉 | 6292篇 |
儿科学 | 7425篇 |
妇产科学 | 3926篇 |
基础医学 | 16434篇 |
口腔科学 | 4274篇 |
临床医学 | 45845篇 |
内科学 | 63982篇 |
皮肤病学 | 8842篇 |
神经病学 | 19939篇 |
特种医学 | 11296篇 |
外国民族医学 | 56篇 |
外科学 | 51409篇 |
综合类 | 30116篇 |
现状与发展 | 117篇 |
一般理论 | 7篇 |
预防医学 | 19791篇 |
眼科学 | 7143篇 |
药学 | 17378篇 |
214篇 | |
中国医学 | 11407篇 |
肿瘤学 | 21328篇 |
出版年
2024年 | 1394篇 |
2023年 | 7011篇 |
2022年 | 7210篇 |
2021年 | 10533篇 |
2020年 | 12127篇 |
2019年 | 6623篇 |
2018年 | 11945篇 |
2017年 | 12359篇 |
2016年 | 12551篇 |
2015年 | 15136篇 |
2014年 | 23798篇 |
2013年 | 24076篇 |
2012年 | 17568篇 |
2011年 | 18440篇 |
2010年 | 19448篇 |
2009年 | 21679篇 |
2008年 | 14175篇 |
2007年 | 12010篇 |
2006年 | 13960篇 |
2005年 | 9865篇 |
2004年 | 7393篇 |
2003年 | 6273篇 |
2002年 | 5533篇 |
2001年 | 6682篇 |
2000年 | 5350篇 |
1999年 | 5285篇 |
1998年 | 4914篇 |
1997年 | 4647篇 |
1996年 | 4266篇 |
1995年 | 4058篇 |
1994年 | 2652篇 |
1993年 | 1908篇 |
1992年 | 1795篇 |
1991年 | 1755篇 |
1990年 | 1389篇 |
1989年 | 1434篇 |
1988年 | 1276篇 |
1987年 | 1058篇 |
1986年 | 1048篇 |
1985年 | 815篇 |
1984年 | 627篇 |
1983年 | 552篇 |
1982年 | 534篇 |
1981年 | 422篇 |
1980年 | 377篇 |
1979年 | 322篇 |
1978年 | 333篇 |
1977年 | 401篇 |
1975年 | 279篇 |
1972年 | 305篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
5.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
6.
Elizabeth A. Mosley PhD MPH Amy J. Schulz PhD MPH MSW Lisa H. Harris MD PhD Barbara A. Anderson PhD 《Women & health》2020,60(7):806-820
ABSTRACT Abortion is legal in South Africa, but negative abortion attitudes remain common and are poorly understood. We used nationally representative South African Social Attitudes Survey data to analyze abortion attitudes in the case of fetal anomaly and in the case of poverty from 2007 to 2016 (n = 20,711; ages = 16+). We measured correlations between abortion attitudes and these important predictors: religiosity, attitudes about premarital sex, attitudes about preferential hiring and promotion of women, and attitudes toward family gender roles. Abortion acceptability for poverty increased over time (b = 0.05, p < .001), but not for fetal anomaly (b = ?0.008, p = .284). Highly religious South Africans reported lower abortion acceptability in both cases (Odds Ratio (OR)anomaly = 0.85, p = .015; ORpoverty = 0.84, p = .02). Premarital sex acceptability strongly and positively predicted abortion acceptability (ORanomaly = 2.63, p < .001; ORpoverty = 2.46, p < .001). Attitudes about preferential hiring and promotion of women were not associated with abortion attitudes, but favorable attitudes about working mothers were positively associated with abortion acceptability for fetal anomaly ((ORanomaly = 1.09, p = .01; ORpoverty = 1.02, p = .641)). Results suggest negative abortion attitudes remain common in South Africa and are closely tied to religiosity, traditional ideologies about sexuality, and gender role expectations about motherhood. 相似文献
7.
目的:分析糖尿病视网膜病变合并黄斑水肿联合采用激光与复方血栓通胶囊治疗的临床疗效。方法:选取我院2017年1月—2019年1月收治的200例糖尿病视网膜病变合并黄斑水肿患者为研究对象,随机分为两组。对照组单独行激光治疗,观察组于对照组基础上联合复方血栓通胶囊治疗,对比两组临床疗效、治疗前后IL-6(白介素-6)、VEGF(血管内皮生长因子)、NOS(血清一氧化氮合成酶)水平变化情况。结果:对照组总有效率(68.00%,68/100)较观察组总有效率(98.00%,98/100)更高(P<0.05);与对照组对比,观察组治疗后NOS水平更高,IL-6、VEGF水平更低(P<0.05)。结论:糖尿病视网膜病变合并黄斑水肿联合采用激光与复方血栓通胶囊治疗的临床疗效显著,值得推广。 相似文献
8.
9.
目的:综述运动系统软组织损伤引起慢性疼痛的各种治疗方法的研究进展。资料来源:应用计算机检索Medline1980—01/2006—04与运动系统软组织损伤引起慢性疼痛的治疗相关文章,检索词“Soft tissue injury,pain.chronic,comprehensive therapy”,并限定文章语言种类为“English”;同时计算机检索中国期刊全文数据库1994—01/2006-04期间的相关文章,检索词“软组织损伤、慢性疼痛、治疗方法”,并限定语言种类为中文。同时手工查阅相关书籍。资料选择:对资料进行初审,所选文献内容符合:①软组织损伤引起的慢性疼痛药物治疗的研究。②软组织损伤引起的慢性疼痛微创治疗的研究。③软组织损伤引起的慢性疼痛运动疗法的研究。④软组织损伤引起的慢性疼痛心理治疗的研究。⑤软组织损伤引起的慢性疼痛其他疗法的研究。排除重复性研究的文献。资料提炼:共收集到40篇关于软组织损伤引起的慢性疼痛治疗方法的文献,均为全文,23篇符合纳入标准,排除17篇重复性研究。同时录入书籍3本。资料综合:软组织损伤引起的慢性疼痛的产生是生理、心理及社会因素复杂结合的结果,个体表现差异较大,目前尚无特效治疗方法,常用的治疗方法有:药物治疗、微创治疗、运动疗法、心理治疗、物理疗法及其他疗法。结论:对于软组织损伤引起的慢性疼痛的治疗必须以整体的观点对其进行合理的评估和个体化治疗,才能收到良好的效果。 相似文献
10.